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Abstract
Small bowel contractility may be more prominent in obese subjects, such that there is enhanced
nutrient absorption and hunger stimulation. However, there is little evidence to support this. This
study examined in vitro small bowel contractility in obese patients versus non-obese patients.
Samples of histologically normal small bowel were obtained at laparoscopic Roux-en-Y gastric
bypass from obese patients. Control specimens were taken from non-obese patients undergoing
small bowel resection for benign disease or formation of an ileal pouch-anal anastamosis. Samples
were transported in a pre-oxygenated Krebs solution. Microdissected circular smooth muscle
strips were suspended under 1 g of tension in organ baths containing Krebs solution oxygenated
with 95% O2/5% CO2 at 37°C. Contractile activity was recorded using isometric transducers at
baseline and in response to receptor-mediated contractility using prostaglandin F2a, a nitric oxide
donor and substance P under both equivocal and non-adreneregic, non-cholinergic conditions
(guanethidine and atropine).
Following equilibration, the initial response to the cholinergic agonist carbachol (0.1 mmol/L) was
significantly increased in the obese group (n = 63) versus the lean group (n = 61) with a mean
maximum response: weight ratio of 4.58 ± 0.89 vs 3.53 ± 0.74; (p = 0.032). Following washout and
re-calibration, cumulative application of substance P and prostaglandin F2a produced
concentration-dependent contractions of human small bowel smooth muscle strips. Contractile
responses of obese small bowel under equivocal conditions were significantly increased compared
with non-obese small bowel (p < 0.05 for all agonists). However, no significant differences were
shown between the groups when the experiments were performed under NANC conditions.
There were no significant differences found between the groups when challenged with nitric oxide,
under either equivocal or NANC conditions.
Stimulated human small bowel contractility is increased in obese patients suggesting faster enteric
emptying and more rapid intestinal transit. This may translate into enhanced appetite and reduced
satiety.
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Introduction
The development of obesity results from a person's inad-
equate energy expenditure and/or excessive caloric intake.
In relation to caloric intake, the gastrointestinal (GI) sys-
tem plays a vital role in the controlling nutrient ingestion,
digestion, and absorption. These functions depend on an
intact, coordinated GI motility, which not only regulates
the rates at which nutrients are processed but also partici-
pates in the control of appetite and satiety. Alterations in
GI motility have been observed in obese patients [1,2],
and these alterations could be contributing factors to the
development and maintenance of obesity and changed
eating behaviors.
There are conflicting reports regarding the role of the
small intestine in obesity. Two major areas of relevance to
the whole debate are small intestinal motility and absorp-
tion of nutrients. Intestinal transit plays a crucial role in
the absorption of nutrients. Variations in intestinal motil-
ity control the transit and absorption of the ingested nutri-
ents through negative feedback [3,4] and hormonal
methods [5], thus affecting satiety. On the one hand, if
obese patients demonstrate increased intestinal motility
and transit, does this indicate that they have enhanced
absorptive capacity? However, if they have a decreased
transit time, what factor is present that blocks the negative
feedback on satiety in these patients? It has been specu-
lated that the intestinal absorption is more rapid and effi-
cient in obesity, irrespective of the intestinal transit rate,
but the supporting evidence is very limited.
There are very few reports in the literature relating to
investigation of small intestinal motility in the obese. It
has been suggested that the contractile activity of small
intestine is more prominent in the fasting period in obese
subject [6]. Pieramico et al suggested motility distur-
bances in the fasting period, including diminished Phase
I, increased Phase II, and a more distal and less frequent
occurrence of Phase III activity of the migrating motor
complex in association with decreased plasma motilin
concentrations. The significance of these changes is not
fully understood. They may also suggest that the contrac-
tile activity of small intestine is more prominent in the
fasting period in obese subjects. This may be associated
with more efficient absorption of nutrients within the
small intestine or the precipitation of hunger.
The aim of this study was to demonstrate the differences,
if any, between in vitro contractility, stimulated by com-
mon agonists, of small bowel from morbidly obese
patients and that of patients with a normal BMI.
Methods
Patients and tissue preparation
The University Hospital's ethics committee and institu-
tional review board approved this prospective study and
the use of human tissue.
Specimens of histologically normal human small bowel
smooth muscle were obtained at the time of laparoscopic
Roux-en-Y gastric bypass from eight obese patients (5
female, 3 male) with a mean body mass index (BMI) of
48.2 kg/m2 (range 44.2 kg/m2 – 60.3 kg/m2), and a mean
age of 44.25 years (range 29.1 – 60.8 years). Eight control
small bowel specimens were taken from eight non-obese
patients (4 female, 4 male) undergoing either small bowel
resection for benign disease (five patients) or formation of
an ileal pouch-anal anastomosis (three patients). The
mean BMI of the controls was 24.1 kg/m2 (range 20.8 kg/
m2 – 25.4 kg/m2), with a mean age of 38.75 years (range
20.3 – 52.6 years). In the case of specimens resected from
patients with Crohn's disease, the specimen was obtained
from an area proximal to the affected site and was unin-
volved histologically. None of the patients had diabetes or
a known motility disorder.
The specimens were transported to the laboratory in an
oxygenated cold Krebs solution (4°C) and all experiments
were started within one hour of receiving the specimen.
The muscle was stripped of the underlying mucosa and
submucosa, and from each specimen eight strips of circu-
lar smooth muscle approximately 0.5 cm wide × 1.0 cm
long were mounted in 10-ml organ baths containing
Krebs solution of the following composition (mmol/L):
NaCl, 118; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.2; glucose,
11.1; NaHCO3, 24.9, and CaCl2, 2.5, maintained at 37°C
and gased with 95% O2 and 5% CO2. A resting preload of
1 g was applied to each muscle strip, which was then
allowed to equilibrate for one hour. During this time the
Krebs solution was changed every 20 min. Mechanical
activity was recorded using isometric transducers (World
Precision Instruments, Stevenage, Herts, UK). Tension
was continuously monitored and recorded using a
MacLab data acquisition system (AD Instruments, Hast-
ings, UK).
Experimental protocol
After an equilibration period of one hour, the tissues were
exposed to carbachol (0.1 mmol/L) to determine the max-
imal contractile capacity. This carbachol was then washed
out and the preparations left to re-equilibrate for approx-
imately 30 minutes. After this equilibration period, base-
line contractility of the specimens was observed and
recorded for a further 30 minutes.
Receptor-mediated contractions to prostaglandin F2a
(0.01 nmol/L – 1 μmol/L), a nitric oxide donor in theAnnals of Surgical Innovation and Research 2009, 3:4 http://www.asir-journal.com/content/3/1/4
Page 3 of 7
(page number not for citation purposes)
form of Deta-nonoate (NOC18, 0.01 nmol/L – 1 μmol/L)
and substance P (0.01 nmol/L – 1 μmol/L) were then
studied. In a second set of experiments, inhibitory non-
adrenergic non-cholinergic (NANC) neurotransmission
was studied in separate samples of the same specimens.
The NANC conditions were established by adding
guanethidine (3 μmol/L) and atropine (1 μmol/L) to the
organ bath. Receptor-mediated contractions to the above
agonists were then studied separately under these condi-
tions.
All strips were challenged with carbachol (0.1 mmol/L)
towards the end of the experiment to ensure viability and
subsequently the response to 1 μmol/L atropine was
determined for each strip at the end and used as reference
for calculating the responses to the test substances. At least
one preparation for each specimen was used as control
(tissue incubated with the test substance vehicle only).
The tissue was destroyed following experimentation
under the terms of the local guidelines and procedures.
Chemicals
Carbachol, prostaglandin F2a, and substance P were all
purchased from Sigma-Aldrich (Dublin, Ireland). Deta-
nonoate (NOC18) was kindly donated by Professor Cor-
mac Taylor (Conway Institute of Biomolecular and Bio-
medical Research, University College Dublin, Ireland).
Statistical analysis
Results are expressed as percentage of the maximum car-
bachol response. Data are presented as mean ± SEM.
Comparisons between contractile responses were made
using Student's unpaired two-tailed t test or analysis of
variance, when applicable. Differences between groups
were taken to be significant if p < 0.05. The agonist/antag-
onist concentration producing 50% maximal effect (EC50
or IC50), with adjustment by non-linear regression was
calculated using GraphPad Prism version 5.00 for Win-
dows, GraphPad Software, San Diego, California, USA.
Results
A maximally effective concentration of carbachol (0.1
mmol/L), measured as a ratio to the weight of each strip
produced a ratio of 4.39 ± 0.82 (n = 63) in the small
bowel muscle strips from obese patients. In comparison,
the mean ratio for the controls was 3.87 ± 0.84 (n = 61)
and the difference was shown to be statistically significant
(p = 0.029) (Figure 1).
For both sets of experiments, the response to carbachol
was initially used as an indicator of the capacity of indi-
vidual tissues to contract. Responses to the further ago-
nists were then expressed as a percentage of the maximum
carbachol response for each strip, and a mean percentage
response at each concentration was than recoded.
Representation of the significant differences in contractility between small bowel smooth muscle strips from obese and non- obese patients Figure 1
Representation of the significant differences in contractility between small bowel smooth muscle strips from 
obese and non-obese patients. The values given represent a mean value of the ratio of maximum carbachol response for 
each strip to its weight, and the difference is significant. 4.39 ± 0.82 (n = 63) in the small bowel muscle strips from obese 
patients versus 3.87 ± 0.84 (n = 61) in the strips from control patients. (p = 0.029).
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Prostaglandin F2a (Figure 2a) produced a concentration-
dependant increase in contractility as expected. In obese
tissues and under equivocal conditions, prostaglandin
F2a was twice as potent in effecting a contractile response
as it was in the control strips, with an EC50 (95% confi-
dence limits) of 0.74 nmol/L (0.41 – 1.33) and 1.380
nmol/L (0.76 – 2.56) respectively (p < 0.01).
Under NANC conditions (Figure 2b), there was no signif-
icant difference between the obese strips and the controls
when PGF2a was added in cumulative concentrations
with an EC50 of 3.09 nmol/L (0.31 – 29.91) and 3.05
nmol/L (0.20 – 46.13) respectively.
Substance P (Figure 3a) also produced a concentration-
dependant increase in contractility as expected. The addi-
tion of substance P produced a contractile response in
strips from obese patients that was again roughly twice
that of the response in the controls with an EC50 of 10.42
nmol/L (3.81 – 28.47) and 20.09 nmol/L (10.90 – 37.00)
(p < 0.01).
Under NANC conditions, again, there was no significant
difference between the obese and control groups upon the
addition of cumulative concentrations of substance P
(Figure 3b) with an EC50 of 6.27 nmol/L (1.83 – 21.39)
and 6.39 nmol/L (2.81 – 14.56) respectively.
Nitric oxide produced a concentration-dependant relaxa-
tion as expected. For these strips, the evoked contractions
in from both control and obese patients were virtually
abolished by the addition of 1 μmol/L atropine at the end
of each experiment. This was then taken as 100% for each
strip and all other calculations relating to that strip were
recorded as a percentage of this value. In both groups (Fig-
ure 4), the release of nitric oxide lead to a concentration
dependant relaxation of the tissues but there was no sig-
nificant differences between the obese and control groups
with either equivocal or NANC conditions (not shown),
with an IC50 of 2.26 nmol/L and 2.05 nmol/L in the con-
trol and obese groups respectively under equivocal condi-
tions and similar results when performed under NANC
conditions (2.45 nmol/L and 2.13 nmol/L respectively).
Discussion
A fundamental difference in contractility between obese
and non-obese small bowel was found here. The initial
differences seen in response to the muscarinic agonist car-
bachol, a parasympathomimetic that directly stimulates
cholinergic receptors, demonstrate a significant difference
in cholinergic responsiveness between the two groups.
Because of the complexity of the multiple pathways
involved in agonist-induced contraction including cross
talk between cyclic nucleotides and their respective pro-
tein kinases, three very different agonists and also an
inhibitor were chosen to evaluate the hypothesis. Prostag-
landin F2a (a smooth muscle mitogen that promotes
changes in smooth muscle contractility [7]), substance P
(a tachykinin, the response to which is possibly regulated
by the extra-cellular matrix of smooth muscle [8], and
which may also act as a mediator of neurogenic inflam-
mation in the gut [9].) and carbachol (a simple mus-
carinic agonist) act to cause smooth muscle contractility.
This is via diverse mechanisms and yet, there are signifi-
cant differences between obese and non-obese contractil-
ity for all three agonists. The fact that these differences are
abolished under non-adrenergic, non-cholinergic condi-
tions suggests that the differences are neurally mediated.
As expected, nitric oxide produced an inhibitory response
[10], and the finding of no significant difference between
obese and non-obese small bowel either under equivocal
or NANC conditions adds further weight to the hypothe-
sis that these differences are neurally mediated, as NO is
known to act independently of adrenergic and cholinergic
transmission [11].
This approach has the inherent limitations of any in vitro
system. The absence in vitro of any blood supply to the tis-
sue may have a considerable influence on the release,
interaction with and removal of other transmitters not
studied here. The pharmacological induction of contrac-
tility in the initial stages is artificial but by using each strip
as its own control and for comparison, the inherent prob-
lems with standard electrical field stimulation to all strips
may be lessened. Therefore, extrapolation to the clinical
setting should be made with caution.
Whether altered intestinal contractility in the obese affects
neurohormonal mechanisms of the control of satiety war-
rants further investigation. The alterations in the choliner-
gic responsiveness of intestinal smooth muscle in obesity
as demonstrated in this study may result in altered intesti-
nal motility, which in the clinical realm may suggest faster
enteric emptying and more rapid intestinal transit. This in
turn may translate into reduced satiety and enhanced
appetite in the obese. This highlights intestinal pacing and
pharmacological manipulation of small bowel contractil-
ity as potential therapeutic targets in the management of
obesity in the future.
In summary, this study demonstrates that in vitro contrac-
tility in small bowel smooth muscle from obese patients,
induced by common agonists, is significantly enhanced
compared to that from non-obese patients. It is likely that
these differences are adaptive in nature, but this again
remains to be determined. Whether these differences are
indeed neuronal in nature and whether they are central or
peripheral in origin warrants further investigation. One
possible key component to this may be the recently eluci-Annals of Surgical Innovation and Research 2009, 3:4 http://www.asir-journal.com/content/3/1/4
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A. Logarithm concentration-response curves of prostaglandin F2a as measured from strips from obese and control patients Figure 2
A. Logarithm concentration-response curves of prostaglandin F2a as measured from strips from obese and 
control patients. Results are the mean (SD) of 6–8 preparations from different patients, with the response expressed as a 
percentage of the maximal effect of atropine (1 umol/L). The differences demonstrated are statistically significant. B. Logarithm 
concentration-response curves of prostaglandin F2a as measured from strips from obese and control patients under NANC 
conditions. Results are the mean (SD) of 6–8 preparations from different patients, with the response expressed as a percentage 
of the maximal effect of atropine (1 umol/L). There is no statistically significant difference between the groups.
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A. Logarithm concentration-response curves of substance P in strips from obese and control patients Figure 3
A. Logarithm concentration-response curves of substance P in strips from obese and control patients. Results 
shown are the mean of 6–8 strips from differenct patients, and the response is expressed as a percentage of the maximum 
response to carbachol (0.1 mmol/L). The differnces demonstrated are statistically significant. B – Cumulative concentrations of 
substance P have similar potency in obese and control tissues under NANC conditions. Results shown are a mean of 6–8 
patients in each group, expressed as a percentage of the maximum response to carbachol (0.1 mmol/L). There are no statisti-
cally significant differences demonstrated under NANC conditions.
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dated endocannabinoid system which is neurally-medi-
ated and which is known to be over-active in obesity [12]
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Logarithm concentration-response curves of a nitric oxide  donor (deta-nonoate) from obese and control patients Figure 4
Logarithm concentration-response curves of a nitric 
oxide donor (deta-nonoate) from obese and control 
patients. Results shown are a mean of 6–8 patients in each 
group, expressed as a percentage of the maximum response 
to atropine (I micromol/L). A virtually identical graph was 
obtained when the experiment was performed under NANC 
conditions. There are no statistically significant differences 
demonstrated in either group.
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